How Safe Is the COVID-19 Vaccine?

How Safe Is the COVID-19 Vaccine?

While the COVID-19 vaccines now on the market in the United 

States have been shown to be safe and effective, Guest Posting 

reports of unusual adverse events or side effects have raised concerns.

approved an amendment to the Johnson & Johnson COVID-19 

vaccine fact sheet that adds an increased risk of Guillain-Barre 

syndrome, a rare nerve disease. Previous research has linked the J&J vaccine to a rare blood clot.

While such reports may be frightening, they are proof that the 

vaccine safety reporting system is working. They also emphasize 

I have witnessed how uncertainty and fear of potential side effects 

can cause vaccine hesitancy while leading operations for the 

University of Virginia Health System's COVID-19 vaccine program for the past seven months. Understanding how adverse event data is 

collected and what it means for vaccine safety can help consumers 

make more informed health decisions.

Safety monitoring before, during and after approval

Before a new vaccine can be made available to the public, the FDA 

 The methods necessary to test the safety and 

effectiveness of a new drug are the same whether it is approved 

through the traditional FDA approval process or under an Emergency Use Authorization (EUA). By speeding up the regulatory 

process, the EUA can bring the vaccine to the public faster, but there are no shortcuts. All precautions are taken to ensure the safety and efficacy of the vaccine.

Clinical trials of vaccines are divided into four phases. Study investigators are the ones who detect, quantify and document safety 

risks in the first three phases

fewer than 100 patients over several months in a controlled environment. In most cases, most likely side effects are discovered at this point.

After the FDA reviews the Phase 1 data and determines that the 

vaccine is safe enough to be tested further, it will be given to larger 

groups of people over a longer period of time in Phases 2 and 3. Investigators use this phase to determine the best dosing and 

monitoring for any unusual side effects.

If Phase 2 and 3 evidence meets FDA clearance criteria, the vaccine 

The vaccine is tested on much larger groups of people over a long 

period of time, and manufacturers are required to regularly 

monitor and report potential safety issues to the FDA.

In this last step, which is unique, the public can participate in the safety report. 

(VAERS), a national safety surveillance system. While health care 

providers are required to report some types of adverse events, such 

as injuries during vaccination and serious outcomes, anyone can 

make a report. VAERS has identified recent adverse events 

associated with COVID-19 vaccinations, including Guillain-Barre 

Vaccines have a low risk of serious side effects

patients use some drugs that are less commonly used, it takes longer to discover new safety data. For example, the shingles 

vaccine Shringrix was approved in 2017, but it wasn't until March 

2021, after more than 3.7 million patients had received the shot, 

that the FDA reported a possible increased risk of Guillain-Barre syndrome. 

COVID-19 poses a greater threat than vaccine-related adverse reactions

greater risk than they have to during such unusual circumstances as a pandemic. However, there are safety nets for tracking COVID-19 

vaccines that continue to function properly.

The COVID-19 vaccines are extremely safe for the vast majority of people.

similar to the Pfizer and Modern trial samples. In the J&J study, 0.4 

percent of subjects had significant adverse events that were not 

arelated to COVID-19 infection.